应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AXSM Axsome Therapeutics, Inc.
盘后交易 01-09 19:36:46 EST
169.38
+1.83
+1.09%
盘后
170.01
+0.63
+0.37%
19:35 EST
最高
173.78
最低
168.51
成交量
79.38万
今开
169.10
昨收
167.55
日振幅
3.15%
总市值
85.39亿
流通市值
70.92亿
总股本
5,041万
成交额
1.36亿
换手率
1.90%
流通股本
4,187万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Axsome Thera阿尔茨海默病疗法获FDA优先审评
环球市场播报 · 01-01
Axsome Thera阿尔茨海默病疗法获FDA优先审评
Axsome Therapeutics旗下抑郁症疗法扩大适应症获FDA优先审评
智通财经 · 2025-12-31
Axsome Therapeutics旗下抑郁症疗法扩大适应症获FDA优先审评
Axsome Therapeutics获FDA优先审评资格 AXS-05新药审评目标日期定为2026年4月30日
美股速递 · 2025-12-31
Axsome Therapeutics获FDA优先审评资格 AXS-05新药审评目标日期定为2026年4月30日
Axsome公司宣布FDA受理Axs-05治疗阿尔茨海默病激越症状的补充新药申请并授予优先审评资格
美股速递 · 2025-12-31
Axsome公司宣布FDA受理Axs-05治疗阿尔茨海默病激越症状的补充新药申请并授予优先审评资格
Axsome Therapeutics公布Axs-12治疗发作性睡病FDA新药申请前会议纪要 支持NDA提交
美股速递 · 2025-12-31
Axsome Therapeutics公布Axs-12治疗发作性睡病FDA新药申请前会议纪要 支持NDA提交
Axsome Therapeutics第三季度净收入为负4722.9万美元
投资观察 · 2025-11-20
Axsome Therapeutics第三季度净收入为负4722.9万美元
Axsome Therapeutics收购选择性GABA-A受体正向别构调节剂Azd7325以治疗癫痫
美股速递 · 2025-11-06
Axsome Therapeutics收购选择性GABA-A受体正向别构调节剂Azd7325以治疗癫痫
Axsome Therapeutics, Inc.2025财年第二财季实现净利润-47.97百万美元，同比增加39.55%
市场透视 · 2025-08-10
Axsome Therapeutics, Inc.2025财年第二财季实现净利润-47.97百万美元，同比增加39.55%
美股财报 | Axsome Therapeutics发布Q2财报 前半年累计净亏损同比缩小27.30%
同花顺iNews · 2025-08-05
美股财报 | Axsome Therapeutics发布Q2财报 前半年累计净亏损同比缩小27.30%
异动解读 | Axsome Therapeutics股价盘中大跌5.02%，尽管Q2收入超预期
异动解读 · 2025-08-04
异动解读 | Axsome Therapeutics股价盘中大跌5.02%，尽管Q2收入超预期
异动解读 | Axsome Therapeutics盘前大涨5.80%，投资者期待季度财报
异动解读 · 2025-08-04
异动解读 | Axsome Therapeutics盘前大涨5.80%，投资者期待季度财报
Axsome Therapeutics, Inc.盘中异动 急速下跌5.00%
市场透视 · 2025-03-10
Axsome Therapeutics, Inc.盘中异动 急速下跌5.00%
Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。
金融界 · 2025-03-03
Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。
瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。
金融界 · 2025-02-27
瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。
异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因
异动解读 · 2025-02-26
异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因
Axsome Therapeutics, Inc.盘中异动 下午盘快速下挫5.04%
市场透视 · 2025-02-26
Axsome Therapeutics, Inc.盘中异动 下午盘快速下挫5.04%
Axsome Therapeutics, Inc.盘中异动 早盘股价大跌5.15%报130.65美元
市场透视 · 2025-02-24
Axsome Therapeutics, Inc.盘中异动 早盘股价大跌5.15%报130.65美元
Axsome Therapeutics, Inc.盘中异动 快速上涨5.02%
市场透视 · 2025-02-22
Axsome Therapeutics, Inc.盘中异动 快速上涨5.02%
Axsome Therapeutics, Inc.2024财年实现净利润-2.87亿美元，同比减少20.08%
市场透视 · 2025-02-22
Axsome Therapeutics, Inc.2024财年实现净利润-2.87亿美元，同比减少20.08%
Truist Securities：维持Axsome Therapeutics(AXSM.US)评级，由买入调整至买入评级, 目标价由190.00美元调整至200.00美元。
金融界 · 2025-02-20
Truist Securities：维持Axsome Therapeutics(AXSM.US)评级，由买入调整至买入评级, 目标价由190.00美元调整至200.00美元。
加载更多
公司概况
公司名称：
Axsome Therapeutics, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Axsome Therapeutics, Inc.成立于2012年1月。该公司是一家临床阶段的生物制药企业，开发新的治疗疼痛和其他中枢神经系统或中枢神经系统，疾病管理。通过专注于这一治疗领域，他们正在解决显著和不断增长的市场，其中目前的治疗选择是有限或不充分的。他们的目标是成为一个完全集成的生物制药公司开发和商业化的拓展提供给医护人员的治疗方案，提高生活疼痛和其他中枢神经系统疾病患者的生命分化疗法。
发行价格：
--
{"stockData":{"symbol":"AXSM","market":"US","secType":"STK","nameCN":"Axsome Therapeutics, Inc.","latestPrice":169.38,"timestamp":1767992400000,"preClose":167.55,"halted":0,"volume":793797,"hourTrading":{"tag":"盘后","latestPrice":170.0136,"preClose":169.38,"latestTime":"19:35 EST","volume":25360,"amount":4296135.145599999,"timestamp":1768005318322},"delay":0,"floatShares":41872836,"shares":50412640,"eps":-4.662952,"marketStatus":"盘后交易","change":1.83,"latestTime":"01-09 19:36:46 EST","open":169.1,"high":173.78,"low":168.51,"amount":135965669.96643,"amplitude":0.031453,"askPrice":172.68,"askSize":11,"bidPrice":168,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.662952,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768006800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1447909200000,"exchange":"NASDAQ","adjPreClose":167.55,"preHourTrading":{"tag":"盘前","latestPrice":169.14,"preClose":167.55,"latestTime":"09:29 EST","volume":1251,"amount":210577.47731999998,"timestamp":1767968970034},"postHourTrading":{"tag":"盘后","latestPrice":170.0136,"preClose":169.38,"latestTime":"19:35 EST","volume":25360,"amount":4296135.145599999,"timestamp":1768005318322},"volumeRatio":0.809263,"impliedVol":0.3629,"impliedVolPercentile":0.0598},"requestUrl":"/m/hq/s/AXSM","defaultTab":"news","newsList":[{"id":"2600291709","title":"Axsome Thera阿尔茨海默病疗法获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2600291709","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600291709?lang=zh_cn&edition=full","pubTime":"2026-01-01 04:54","pubTimestamp":1767214440,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics（AXSM）周三尾盘大涨23.3%，此前该公司的阿尔茨海默病疗法获FDA优先审评。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-01/doc-inhetury3349181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AXSM","SINA","BK4585","BK4007","BK4505"],"gpt_icon":0},{"id":"1105041942","title":"Axsome Therapeutics旗下抑郁症疗法扩大适应症获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1105041942","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105041942?lang=zh_cn&edition=full","pubTime":"2025-12-31 23:22","pubTimestamp":1767194526,"startTime":"0","endTime":"0","summary":"2026年4月30日设定为目标审评完成日期。","market":"us","thumbnail":"https://static.tigerbbs.com/7fe4f8bfff8fbadfc21a2642c0b8904c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/7fe4f8bfff8fbadfc21a2642c0b8904c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a4ec79ab5d488023feba22ccc95575ec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1387917.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Axsome旗下抑郁症疗法扩大适应症获FDA优先审评","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["AXSM"],"gpt_icon":1},{"id":"1116227023","title":"Axsome Therapeutics获FDA优先审评资格 AXS-05新药审评目标日期定为2026年4月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1116227023","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116227023?lang=zh_cn&edition=full","pubTime":"2025-12-31 20:02","pubTimestamp":1767182521,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已正式授予Axsome Therapeutics公司旗下在研药物AXS-05优先审评资格，并为该药物设定了处方药用户收费法案目标行动日期为2026年4月30日。这一重要监管进展意味着AXS-05的新药申请将进入加速审评通道。FDA此次设定的PDUFA日期，标志着监管机构将于2026年4月30日前完成对AXS-05申请的审查并做出最终决定。此次监管里程碑为Axsome Therapeutics的核心产品管线注入了强劲动力。公司将继续与FDA保持密切沟通，积极推进AXS-05的审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AXSM","BK4585","BK4505"],"gpt_icon":0},{"id":"1189784894","title":"Axsome公司宣布FDA受理Axs-05治疗阿尔茨海默病激越症状的补充新药申请并授予优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1189784894","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189784894?lang=zh_cn&edition=full","pubTime":"2025-12-31 20:00","pubTimestamp":1767182423,"startTime":"0","endTime":"0","summary":"生物制药企业Axsome Therapeutics, Inc.近日宣布，美国食品药品监督管理局已正式受理其核心产品Axs-05针对阿尔茨海默病相关激越症状治疗的补充新药申请。此次申报同时获得FDA授予的优先审评资格，审评周期将缩短至6个月。数据显示，Axs-05在改善阿尔茨海默病患者激越症状方面表现出显著疗效，且安全性特征良好。若最终获批，Axs-05将成为首个针对阿尔茨海默病激越症状的药物治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AXSM","BK4505","BK4585"],"gpt_icon":0},{"id":"1112437124","title":"Axsome Therapeutics公布Axs-12治疗发作性睡病FDA新药申请前会议纪要 支持NDA提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1112437124","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112437124?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:56","pubTimestamp":1767182176,"startTime":"0","endTime":"0","summary":"生物制药公司Axsome Therapeutics近日披露，针对其候选药物Axs-12用于治疗发作性睡病的研发进展，已获得美国食品药品监督管理局（FDA）新药申请前会议纪要。该纪要内容积极，为后续正式提交新药申请（NDA）提供了关键支持。\n此次会议纪要确认了Axs-12临床开发项目的关键要素，并明确了NDA提交的数据要求。公司表示，将基于与FDA达成的共识，积极推进Axs-12的NDA准备工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM","BK4007","BK4505","BK4585"],"gpt_icon":0},{"id":"1143782751","title":"Axsome Therapeutics第三季度净收入为负4722.9万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143782751","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143782751?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:28","pubTimestamp":1763569697,"startTime":"0","endTime":"0","summary":"11月3日——Axsome Therapeutics第三季度运营费用为2.17101亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM","BK4505","BK4585","BK4007"],"gpt_icon":0},{"id":"1146864476","title":"Axsome Therapeutics收购选择性GABA-A受体正向别构调节剂Azd7325以治疗癫痫","url":"https://stock-news.laohu8.com/highlight/detail?id=1146864476","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146864476?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:01","pubTimestamp":1762430500,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics收购选择性GABA-A受体正向别构调节剂Azd7325以治疗癫痫","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","LU0823399737.USD","LU0058720904.USD","LU1301847155.USD","LU0792757196.USD","LU0949170426.SGD","LU1019634622.SGD","LU0432979614.USD","AXSM","LU1267930227.SGD","LU2108987350.USD","LU0889565080.SGD","IE00BKPKM643.USD","LU0496365809.HKD","LU0211327993.USD","LU0029864427.USD","LU0757432116.USD","LU2089984988.USD","LU0823416689.USD","SG9999001176.SGD","LU2279689827.SGD","IE00BJJMRZ35.SGD","LU0128525929.USD","LU0203347892.USD","LU0557290698.USD","BK4585","LU0526926950.USD","LU0499090636.EUR","LU0963555726.SGD","IE00B4R5TH58.HKD","LU1496350171.SGD","LU0997586432.USD","LU1153585028.USD","LU2133065610.SGD","LU1983299246.USD","LU0345777147.USD","LU0310799852.SGD","LU0784383803.USD","LU0972486137.USD","LU1814569148.SGD","LU1051770623.HKD","LU2114397693.USD","IE0034235188.USD","LU1261432733.SGD","LU1015430645.USD","LU0738911758.USD","LU1989771016.USD","LU2023251221.USD","LU0052756011.USD","LU0553294199.USD","LU0114720955.EUR","LU1023059063.AUD","LU1061106388.HKD","LU0266013472.USD","LU1481600234.SGD","IE00BJT1NW94.SGD","LU0784384876.USD","LU0158827948.USD","LU1291159041.SGD","LU1880407132.USD","LU1487256676.USD","LU0345777659.USD","03165","LU1084165304.USD","LU0661504455.SGD","LU0211326755.USD","LU0708994859.HKD","LU1989772923.USD","LU0171293334.USD","LU1119994496.HKD","LU1003077747.HKD","LU0784385170.HKD","LU1267930573.SGD","LU0882574055.USD","LU0122379950.USD","LU1003076772.USD","IE00B2B36J28.USD","LU2112291526.USD","LU0047473722.EUR","LU0128525689.USD","LU0949170772.SGD","LU1064927863.SGD","LU2089283258.USD","LU1267930490.SGD","LU1267930813.SGD","LU1078025761.USD","LU1880407215.USD","LU1153584641.USD","LU0289739699.SGD","BK4505","LU2468319806.SGD","LU1019632923.USD","LU0011850046.USD","LU1323610961.USD","LU2089284900.SGD","SG9999001176.USD","LU1496350502.SGD","BK5011","LU0976567544.SGD","IE00BFTCPJ56.SGD","LU0575583348.USD","IE0002141913.USD","SGXZ57979304.SGD","LU0545039389.USD","LU0310800965.SGD","LU1989772840.SGD","LU0211326839.USD","BK4007","LU0211328371.USD","LU1481599808.USD","SG9999013999.USD","LU0203345920.USD","LU0969580561.USD","LU0077335932.USD","LU0957799991.USD","LU0640478417.SGD","LU0047473722.SGD","LU0964806797.USD","IE0009355771.USD","LU1057294990.SGD","LU0889566641.SGD","AZN.UK","LU2091194634.USD","LU0310800379.SGD","LU0784385840.USD","IE00B3T34201.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"2558502944","title":"Axsome Therapeutics, Inc.2025财年第二财季实现净利润-47.97百万美元，同比增加39.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558502944","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558502944?lang=zh_cn&edition=full","pubTime":"2025-08-10 00:01","pubTimestamp":1754755290,"startTime":"0","endTime":"0","summary":"8月10日，Axsome Therapeutics, Inc.公布财报，公告显示公司2025财年第二财季净利润为-47.97百万美元，同比增加39.55%；其中营业收入为1.50亿美元，同比增加72.08%，每股基本收益为-0.97美元。机构评级：截至2025年8月10日，当前有19家机构对Axsome Therapeutics, Inc.目标价做出预测，其中目标均价为176.83美元，其中最低目标价为144.00美元，最高目标价为200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000330a47efc45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000330a47efc45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","LENZ"],"gpt_icon":0},{"id":"2557535404","title":"美股财报 | Axsome Therapeutics发布Q2财报 前半年累计净亏损同比缩小27.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557535404","media":"同花顺iNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557535404?lang=zh_cn&edition=full","pubTime":"2025-08-05 12:00","pubTimestamp":1754366409,"startTime":"0","endTime":"0","summary":"axsome therapeutics发布Q2财报，2025财年前六月累计收入2.72亿美元，去年同期累计收入为1.62亿美元，同比增长67.43%。axsome therapeutics, Inc.成立于2012年1月。该公司是一家临床阶段的生物制药企业，开发新的治疗疼痛和其他中枢神经系统或中枢神经系统，疾病管理。通过专注于这一治疗领域，他们正在解决显著和不断增长的市场，其中目前的治疗选择是有限或不充分的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805120513a475b7d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805120513a475b7d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","LENZ"],"gpt_icon":0},{"id":"1107727546","title":"异动解读 | Axsome Therapeutics股价盘中大跌5.02%，尽管Q2收入超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1107727546","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107727546?lang=zh_cn&edition=full","pubTime":"2025-08-04 21:54","pubTimestamp":1754315688,"startTime":"0","endTime":"0","summary":"生物制药公司Axsome Therapeutics今日盘中股价大跌5.02%，尽管公司第二季度财报显示收入超出市场预期。根据公司发布的财报，Axsome第二季度调整后每股亏损0.97美元，好于分析师平均预期的亏损1.10美元。尽管收入增长强劲，但投资者似乎对公司持续亏损感到担忧。值得注意的是，尽管短期股价承压，华尔街分析师仍普遍看好该公司，给予\"买入\"评级，12个月目标价中位数为181.50美元，较当前股价有显著上行空间。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"gpt_icon":0},{"id":"1146791883","title":"异动解读 | Axsome Therapeutics盘前大涨5.80%，投资者期待季度财报","url":"https://stock-news.laohu8.com/highlight/detail?id=1146791883","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146791883?lang=zh_cn&edition=full","pubTime":"2025-08-04 18:32","pubTimestamp":1754303554,"startTime":"0","endTime":"0","summary":"美国生物制药公司Axsome Therapeutics, Inc.今日盘前股价大涨5.80%，引发市场广泛关注。根据财经数据提供商FactSet Research Systems Inc.的信息，Axsome Therapeutics计划于今日（周一）上午7:00发布2025年第二季度财报。分析师预期Axsome Therapeutics本季度每股亏损1.06美元。尽管预期仍为亏损，但投资者似乎对公司的业绩报告持乐观态度。生物制药公司的股价常常受到财报、临床试验结果和监管决定等因素的显著影响。投资者可能正在期待公司在财报电话会议上披露的最新研发进展、市场策略或财务状况的积极信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"gpt_icon":0},{"id":"2518277592","title":"Axsome Therapeutics, Inc.盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277592","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518277592?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:42","pubTimestamp":1741617767,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时42分，Axsome Therapeutics, Inc.股票出现异动，股价大幅跳水5.00%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3487.28%、761.92%、648.51%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.06%、41.36%、40.33%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","LENZ","BK4585","BK4007","AXSM","BK4139"],"gpt_icon":0},{"id":"2516579633","title":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516579633","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516579633?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006288,"startTime":"0","endTime":"0","summary":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","AXSM"],"gpt_icon":0},{"id":"2514857535","title":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857535","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514857535?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:11","pubTimestamp":1740586273,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27001148413683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["161121","AXSM","LENZ"],"gpt_icon":0},{"id":"1132091385","title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1132091385","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132091385?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:04","pubTimestamp":1740510275,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.(AXSM)今日盘中大跌5.03%,引发了市场广泛关注。\n\nAXSM是一家致力于开发治疗中枢神经系统疾病的新疗法的生物制药公司。从最新财报数据看,公司营收3.86亿美元,净利润则达-2.87亿美元,每股亏损5.99美元。较高的亏损可能是导致股价下跌的主要原因之一。\n\n同时,分析师普遍认为,该公司股价目前市盈率过高,约为-20.76倍,短期内增长动能不足,估值面临压力。机构方面给予100%买入评级,但显然并没能阻止股价下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"gpt_icon":0},{"id":"2514139048","title":"Axsome Therapeutics, Inc.盘中异动 下午盘快速下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514139048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514139048?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:01","pubTimestamp":1740510114,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时01分，Axsome Therapeutics, Inc.股票出现异动，股价快速下跌5.04%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1940.33%、1162.55%、995.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp，振幅分别为241.19%、112.90%、87.83%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260301549892802b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260301549892802b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","BK4585","BK4505","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2513778342","title":"Axsome Therapeutics, Inc.盘中异动 早盘股价大跌5.15%报130.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778342","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513778342?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:04","pubTimestamp":1740409483,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时04分，Axsome Therapeutics, Inc.股票出现异动，股价大幅下跌5.15%。截至发稿，该股报130.65美元/股，成交量22.0085万股，换手率0.45%，振幅4.89%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Pepgen Inc.、Telix Pharmaceutic、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为160.26%、70.68%、25.66%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230443abdb160d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230443abdb160d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","BK4505","BK4139","LENZ","BK4585","BK4007"],"gpt_icon":0},{"id":"2513902542","title":"Axsome Therapeutics, Inc.盘中异动 快速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513902542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513902542?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:28","pubTimestamp":1740155326,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时28分，Axsome Therapeutics, Inc.股票出现异动，股价大幅拉升5.02%。截至发稿，该股报135.58美元/股，成交量43.6884万股，换手率0.90%，振幅5.52%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Nkgen Biotech, Inc.、Invivyd, Inc.、Osr Holdings, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为201.91%、142.45%、119.77%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为70.43%、57.50%、48.19%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002847abd7c910&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002847abd7c910&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","BK4585","LENZ","BK4007","BK4139","BK4505"],"gpt_icon":0},{"id":"2513689292","title":"Axsome Therapeutics, Inc.2024财年实现净利润-2.87亿美元，同比减少20.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513689292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513689292?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:00","pubTimestamp":1740153636,"startTime":"0","endTime":"0","summary":"2月22日，Axsome Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.87亿美元，同比减少20.08%；其中营业收入为3.86亿美元，同比增加42.44%，每股基本收益为-5.99美元。机构评级：截至2025年2月22日，当前有17家机构对Axsome Therapeutics, Inc.目标价做出预测，其中目标均价为166.47美元，其中最低目标价为121.00美元，最高目标价为200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000053a24ec476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000053a24ec476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","LENZ"],"gpt_icon":0},{"id":"2512748730","title":"Truist Securities：维持Axsome Therapeutics(AXSM.US)评级，由买入调整至买入评级, 目标价由190.00美元调整至200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512748730","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512748730?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:11","pubTimestamp":1739985063,"startTime":"0","endTime":"0","summary":"Truist Securities：维持Axsome Therapeutics(AXSM.US)评级，由买入调整至买入评级, 目标价由190.00美元调整至200.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20011148268171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","AXSM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.axsome.com","stockEarnings":[{"period":"1week","weight":-0.0826},{"period":"1month","weight":0.1538},{"period":"3month","weight":0.3766},{"period":"6month","weight":0.5374},{"period":"1year","weight":1.0292},{"period":"ytd","weight":-0.0826}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.1057},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Axsome Therapeutics, Inc.成立于2012年1月。该公司是一家临床阶段的生物制药企业，开发新的治疗疼痛和其他中枢神经系统或中枢神经系统，疾病管理。通过专注于这一治疗领域，他们正在解决显著和不断增长的市场，其中目前的治疗选择是有限或不充分的。他们的目标是成为一个完全集成的生物制药公司开发和商业化的拓展提供给医护人员的治疗方案，提高生活疼痛和其他中枢神经系统疾病患者的生命分化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":0.066091},{"month":2,"riseRate":0.2,"avgChangeRate":-0.029639},{"month":3,"riseRate":0.3,"avgChangeRate":0.057923},{"month":4,"riseRate":0.7,"avgChangeRate":0.151343},{"month":5,"riseRate":0.3,"avgChangeRate":-0.053003},{"month":6,"riseRate":0.6,"avgChangeRate":0.124079},{"month":7,"riseRate":0.5,"avgChangeRate":-0.030066},{"month":8,"riseRate":0.6,"avgChangeRate":0.05275},{"month":9,"riseRate":0.5,"avgChangeRate":-0.019558},{"month":10,"riseRate":0.5,"avgChangeRate":0.012145},{"month":11,"riseRate":0.7,"avgChangeRate":0.154442},{"month":12,"riseRate":0.727273,"avgChangeRate":0.190318}],"exchange":"NASDAQ","name":"Axsome Therapeutics, Inc.","nameEN":"Axsome Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Axsome Therapeutics, Inc.,AXSM,Axsome Therapeutics, Inc.股票,Axsome Therapeutics, Inc.股票老虎,Axsome Therapeutics, Inc.股票老虎国际,Axsome Therapeutics, Inc.行情,Axsome Therapeutics, Inc.股票行情,Axsome Therapeutics, Inc.股价,Axsome Therapeutics, Inc.股市,Axsome Therapeutics, Inc.股票价格,Axsome Therapeutics, Inc.股票交易,Axsome Therapeutics, Inc.股票购买,Axsome Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}